March Altus Capital Management LP continued to hold its position in shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 8,599 shares of the biopharmaceutical company’s stock at the end of the second quarter. Alexion Pharmaceuticals comprises 7.8% of March Altus Capital Management LP’s holdings, making the stock its 7th largest position. March Altus Capital Management LP’s holdings in Alexion Pharmaceuticals were worth $1,004,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Meeder Asset Management Inc. acquired a new stake in Alexion Pharmaceuticals during the first quarter worth $114,000. NEXT Financial Group Inc increased its stake in Alexion Pharmaceuticals by 66.1% in the second quarter. NEXT Financial Group Inc now owns 1,106 shares of the biopharmaceutical company’s stock worth $129,000 after buying an additional 440 shares in the last quarter. Dodge & Cox acquired a new stake in Alexion Pharmaceuticals during the first quarter worth $253,000. Nikko Asset Management Americas Inc. acquired a new stake in Alexion Pharmaceuticals during the first quarter worth $297,000. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in Alexion Pharmaceuticals during the first quarter worth $418,000. 96.34% of the stock is currently owned by institutional investors and hedge funds.
Shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) traded down 1.76% during midday trading on Wednesday, reaching $123.76. 1,380,418 shares of the company’s stock were exchanged. The stock has a market cap of $27.75 billion, a P/E ratio of 310.95 and a beta of 1.08. The company’s 50-day moving average is $130.16 and its 200-day moving average is $135.38. Alexion Pharmaceuticals Inc. has a one year low of $110.56 and a one year high of $193.45.
Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.17 by $0.04. The company earned $753 million during the quarter, compared to analyst estimates of $743.18 million. Alexion Pharmaceuticals had a net margin of 3.19% and a return on equity of 10.02%. Alexion Pharmaceuticals’s revenue for the quarter was up 18.4% on a year-over-year basis. During the same period in the prior year, the business earned $1.44 EPS. Equities analysts expect that Alexion Pharmaceuticals Inc. will post $4.64 earnings per share for the current fiscal year.
ALXN has been the topic of a number of recent research reports. Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and issued a $228.00 target price on shares of Alexion Pharmaceuticals in a research report on Tuesday, May 31st. Vetr downgraded shares of Alexion Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $171.50 target price on the stock. in a research report on Thursday, June 2nd. Morgan Stanley reaffirmed an “overweight” rating and issued a $189.00 target price (down from $203.00) on shares of Alexion Pharmaceuticals in a research report on Tuesday, June 7th. BMO Capital Markets reaffirmed a “buy” rating and issued a $160.00 target price (down from $168.00) on shares of Alexion Pharmaceuticals in a research report on Tuesday, June 7th. Finally, Brean Capital reaffirmed a “buy” rating on shares of Alexion Pharmaceuticals in a research report on Tuesday, June 7th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $178.32.
In other news, EVP Carsten Thiel sold 3,225 shares of the stock in a transaction dated Tuesday, September 13th. The stock was sold at an average price of $128.67, for a total value of $414,960.75. Following the transaction, the executive vice president now owns 40,354 shares in the company, valued at approximately $5,192,349.18. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Heidi L. Wagner sold 222 shares of the stock in a transaction dated Monday, August 8th. The shares were sold at an average price of $137.14, for a total value of $30,445.08. Following the completion of the transaction, the senior vice president now owns 32,115 shares in the company, valued at approximately $4,404,251.10. The disclosure for this sale can be found here. 4.41% of the stock is owned by insiders.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.